Relationship of proadrenomedullin N terminal 20 peptide and the other vasoconstrictive substance in patients with chronic heart failure

费宇行,朱智明,高连如,徐洪涛,陈永鹏,杨晔,石湘芸,唐朝枢
DOI: https://doi.org/10.3760/j:issn:0253-3758.2003.08.013
2003-01-01
Abstract:Objective The novel hypotensive peptide, proadrenomedullin N-terminal 20 peptide (PAMP) is processed from the adrenomedullin precursor The PAMP has many function on cardiovascular physiology In this study the plasma levels in the patients with heart failure(HF) were investigated and the pathophysiological effect was discussed Methods Venous blood samples at rest were obtained from patients with HF in New York Heart Association functional classes II and III and from normal subjects The plasma levels of PAMP, angiotensin II(Ang II) , endothilin(ET) were measured with radioimmunoassay and norepinephrine(NE)?epinephrine(E) were measured with HPLC Left ventricular ejection fraction(LVEF) and Left ventricular end diastolic diameter (LVEDD) were measured by echocardiography in all the patients Results The mean plasma level of PAMP was 18 42±2 33ng/L in control group, and 29 37±3 14 ng/L in HF group ,which was 1 53 times higher in HF than that in control group (P0 05) There was a positive correlation between plasma levels of PAMP and Ang II,ET,NE,E(P0 05) significantly LVEF inversely correlated with plasma levels of PAMP (P0 05) Conclusion The plasma levels of PAMP were higher in HF patients than that in control group The vasoconstrictive substance such as Ang II probably be related to its synthesis or secretion, which may involved in the pathophysiological process of HF The elevation of plasma level of PAMP may play the protective role for the patients with HF
What problem does this paper attempt to address?